Literature DB >> 31515542

The IL-1 family of cytokines and receptors in rheumatic diseases.

Charles Anthony Dinarello1,2.   

Abstract

More than any other cytokine family, the 11 members of the IL-1 family are associated with innate immune responses, which occur in acute inflammation and chronic inflammatory conditions such as rheumatic diseases. In many rheumatic diseases, the severity of the condition can result from the balance between the pro-inflammatory and anti-inflammatory members of the IL-1 family. Pro-inflammatory family members (IL-1α, IL-1β, IL-18, IL-33, IL-36α, IL-36β and IL-36γ) are found in the articular environment during arthritis and often correlate with the degree of inflammation present. IL-1β has emerged as pivotal for promoting inflammation, particularly in autoinflammatory diseases, whereas IL-1α and the IL-36 subfamily are associated with skin diseases. IL-33 regulates T helper 2 (TH2) cell-mediated diseases, in sharp contrast to IL-18, which mainly regulates TH1 cell-mediated responses. The IL-1 family also contains four members that suppress inflammation: two specific receptor antagonists (IL-1 receptor antagonist (IL-1Ra) and IL-36 receptor antagonist (IL-36Ra)), and two members that broadly suppress innate inflammation by non-specifically reducing several cytokines and chemokines (IL-37 and IL-38). In this Review, each of the eleven IL-1 family cytokines and their receptors are discussed, along with their putative roles in rheumatic disease and therapeutic options for targeting or promoting these cytokines.

Entities:  

Year:  2019        PMID: 31515542     DOI: 10.1038/s41584-019-0277-8

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  77 in total

1.  PASylation of IL-1 receptor antagonist (IL-1Ra) retains IL-1 blockade and extends its duration in mouse urate crystal-induced peritonitis.

Authors:  Nicholas E Powers; Benjamin Swartzwelter; Carlo Marchetti; Dennis M de Graaf; Alexandra Lerchner; Martin Schlapschy; Rajiv Datar; Uli Binder; Carl K Edwards; Arne Skerra; Charles A Dinarello
Journal:  J Biol Chem       Date:  2019-12-09       Impact factor: 5.157

2.  IL-18/IL-18R1 promotes circulating fibrocyte differentiation in the aging population.

Authors:  Xiao-Hui Niu; Yun-Peng Xie; Song Yang; Yanchun Chen; Liang Xu; Ying Zhang; Yang Liu
Journal:  Inflamm Res       Date:  2020-03-19       Impact factor: 4.575

3.  The Leucine-Rich Repeat Region of CARMIL1 Regulates IL-1-Mediated ERK Activation, MMP Expression, and Collagen Degradation.

Authors:  Qin Wang; Karambir Notay; Gregory P Downey; Christopher A McCulloch
Journal:  Cell Rep       Date:  2020-06-30       Impact factor: 9.423

Review 4.  Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease.

Authors:  Antonio Abbate; Stefano Toldo; Carlo Marchetti; Jordana Kron; Benjamin W Van Tassell; Charles A Dinarello
Journal:  Circ Res       Date:  2020-04-23       Impact factor: 17.367

Review 5.  IL-36 in chronic inflammation and fibrosis - bridging the gap?

Authors:  Michael Elias; Shuai Zhao; Hongnga T Le; Jie Wang; Markus F Neurath; Clemens Neufert; Claudio Fiocchi; Florian Rieder
Journal:  J Clin Invest       Date:  2021-01-19       Impact factor: 14.808

Review 6.  Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer.

Authors:  Jelmer H van Puffelen; Samuel T Keating; Egbert Oosterwijk; Antoine G van der Heijden; Mihai G Netea; Leo A B Joosten; Sita H Vermeulen
Journal:  Nat Rev Urol       Date:  2020-07-16       Impact factor: 14.432

7.  IL-1β-driven osteoclastogenic Tregs accelerate bone erosion in arthritis.

Authors:  Anaïs Levescot; Margaret H Chang; Julia Schnell; Nathan Nelson-Maney; Jing Yan; Marta Martínez-Bonet; Ricardo Grieshaber-Bouyer; Pui Y Lee; Kevin Wei; Rachel B Blaustein; Allyn Morris; Alexandra Wactor; Yoichiro Iwakura; James A Lederer; Deepak A Rao; Julia F Charles; Peter A Nigrovic
Journal:  J Clin Invest       Date:  2021-09-15       Impact factor: 14.808

Review 8.  Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases.

Authors:  Zoltán Szekanecz; Iain B McInnes; Georg Schett; Szilvia Szamosi; Szilvia Benkő; Gabriella Szűcs
Journal:  Nat Rev Rheumatol       Date:  2021-08-02       Impact factor: 20.543

9.  Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial.

Authors:  Roberto Caricchio; Antonio Abbate; Ivan Gordeev; Jamie Meng; Priscilla Y Hsue; Tuhina Neogi; Roberto Arduino; Daria Fomina; Roman Bogdanov; Tatiana Stepanenko; Pilar Ruiz-Seco; Andrés Gónzalez-García; Yu Chen; Yuhan Li; Sarah Whelan; Stephanie Noviello
Journal:  JAMA       Date:  2021-07-20       Impact factor: 56.272

10.  Human recombinant interleukin-38 suppresses inflammation in mouse models of local and systemic disease.

Authors:  Dennis M de Graaf; Ralph J A Maas; Sanne P Smeekens; Elan Eisenmesser; Jasmina S Redzic; Monique M Helsen; Nicholas E Powers; Suzhao Li; Vassili Kalabokis; Mark S Gresnigt; Leo A B Joosten; Charles A Dinarello; Frank L van de Veerdonk
Journal:  Cytokine       Date:  2020-10-28       Impact factor: 3.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.